On June 15, 2017, following the 2017 Annual Meeting of Stockholders of Chiasma, Inc., the Board of Directors of the company appointed Roni Mamluk, Ph.D. to the Board. Dr. Mamluk will serve as a Class III director of the Company, to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2017 or until her earlier death, resignation or removal. Dr. Mamluk, age 50, served as the Company's Chief Development Officer from March 2015 to March 2017 and has served as a director of Chiasma (Israel) Ltd. since April 2017. Dr. Mamluk served as Chief Executive Officer of the Company from April 2013 to March 2015 and held various roles in the Company from 2006 to April 2013, including Chief Operating Officer and Vice President, Research and Development. She also served as a member of Board from April 2013 to March 2015. Prior to joining the Company, Dr. Mamluk established and led nonclinical research and development at Adnexus Therapeutics, Inc.